Paper Details

  1. Home
  2. Paper Details

Efalizumab for the treatment of psoriatic arthritis.

Author: CaroIvor, GarovoyMarvin, LeungHoi M, MeasePhilip J, PappKim A

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Psoriatic arthritis (PsA) is an inflammatory arthritis linked to psoriasis. Efalizumab, a medication that targets a type of immune cell called T cells, is approved for treating moderate to severe psoriasis. This study aims to investigate whether efalizumab is effective for treating PsA.
Paper Details　
Original Abstract of the Article :
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Efalizumab, a T cell-targeted, recombinant human monoclonal antibody, is approved for the treatment of adult patients with chronic moderate to severe plaque psoriasis. The effect of efalizumab therapy on PsA has not pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2310/7750.2007.00006

データ提供：米国国立医学図書館（NLM）

Efalizumab: A Potential Treatment for Psoriatic Arthritis

Psoriatic arthritis (PsA), a painful and debilitating condition, is like a persistent sandstorm in a desert, causing inflammation and joint damage. This research investigates the potential of efalizumab, a T cell-targeted antibody, to treat PsA. While efalizumab has been approved for plaque psoriasis, its effectiveness in PsA has not been extensively studied. This research aims to bridge this knowledge gap and explore the potential of efalizumab as a treatment option for PsA.

Exploring New Treatment Options for Psoriatic Arthritis

The search for effective treatments for PsA continues. This research sheds light on the potential of efalizumab, a T cell-targeted antibody, to alleviate the symptoms and progression of PsA. The findings could lead to new therapeutic strategies for managing this challenging condition.

Managing Psoriatic Arthritis: A Multifaceted Approach

Psoriatic arthritis is a complex condition, requiring a multifaceted approach to management. This research underscores the importance of exploring new treatment options, such as efalizumab, to improve the quality of life for patients living with PsA. A combination of therapies, including medications, physical therapy, and lifestyle modifications, is often needed to effectively manage this condition.

Dr.Camel's Conclusion

The search for effective treatments for Psoriatic arthritis, a relentless sandstorm in the desert of chronic disease, continues. This research offers a glimpse of hope, highlighting the potential of efalizumab, a T cell-targeted antibody, to provide relief for patients. Continued investigation is essential to understand the full impact of efalizumab on PsA and explore its potential as a valuable therapeutic option.

Date :
  1. Date Completed 2007-07-03
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

17374316

DOI: Digital Object Identifier

10.2310/7750.2007.00006

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.